New Serious Adverse Effects With Alemtuzumab in MS New Serious Adverse Effects With Alemtuzumab in MS

Several new and potentially life-threatening adverse events associated with the use of this novel agent for multiple sclerosis have been reported.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

Authors: Badihian S, Shaygannejad V, Soleimani P, Mirmosayyeb O, Samee Z, Manouchehri N, Esmaeil N Abstract The regulatory role of interleukin (IL) -35 in the immunopathogenesis of multiple sclerosis (MS) is suggested in very few studies. We aimed to measure serum levels of IL-35 among clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) patients and evaluate the associations between this cytokine and the disease clinical course. This cross-sectional study was conducted during 2017 in a referral university clinic. Forty patients and 40 healthy controls were included in the study. The level of IL-35 ...
Source: Journal of Biological Regulators and Homeostatic Agents - Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research
Publication date: Available online 18 October 2018Source: CellAuthor(s): International Multiple Sclerosis Genetics ConsortiumSummaryMultiple sclerosis is a complex neurological disease, with ∼20% of risk heritability attributable to common genetic variants, including>230 identified by genome-wide association studies. Multiple strands of evidence suggest that much of the remaining heritability is also due to additive effects of common variants rather than epistasis between these variants or mutations exclusive to individual families. Here, we show in 68,379 cases and controls that up to 5% of this heri...
Source: Cell - Category: Cytology Source Type: research
Publication date: Available online 20 October 2018Source: Journal of Clinical NeuroscienceAuthor(s): Aaron E. Miller, Xianhao Xu, Richard Macdonell, Steve Vucic, Philippe Truffinet, Myriam Benamor, Karthinathan Thangavelu, Mark S. FreedmanAbstractIn the phase 3 TOWER (NCT00751881) study, teriflunomide 14 mg significantly reduced annualized relapse rate (ARR) and risk of 12-week confirmed disability worsening (12-w CDW) vs placebo in patients with relapsing forms of MS (RMS). The TOWER population included an appreciable proportion of Asian patients. Reductions in ARR and 12-w CDW associated with teriflunomide 14 mg were...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Publication date: Available online 19 October 2018Source: Journal of Clinical NeuroscienceAuthor(s): William Beattie, Bernard Yan, Siddharth SoodAbstractAlemtuzumab is a monoclonal antibody used as a disease modifying agent in relapsing and remitting multiple sclerosis. It has not previously been associated with drug induced liver injury.Here we present a case of a 49 year old female developing drug induced liver injury secondary to alemtuzumab, confirmed upon rechallenge. Our patient developed severe hepatitis within two days of starting alemtuzumab, both initially and upon rechallenge. The alanine aminotransferase peak...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
ConclusionAmong all patients stable on IFN beta therapy and the subset stable on IM IFN beta therapy in particular, those who remained on therapy had significantly better outcomes than those who switched to another IFN beta therapy.FundingBiogen (Cambridge, MA, USA).
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Multiple sclerosis (MS) is a chronic inflammatory demyelination disorder with an immune-mediated pathophysiology that affects the central nervous system (CNS). Like other autoimmune conditions, it has a predilection for female gender. This suggests a gender bias and a possible hormonal association. Inflammation and demyelination are hallmarks of MS. Oligodendrocytes are the myelinating cells of the CNS and these continue to be generated by oligodendrocyte precursor cells (OPCs). The process of remyelination represents a major form of plasticity in the developing adult CNS. Remyelination does occur in MS, but the process is...
Source: European Neurology - Category: Neurology Source Type: research
Drs Stephen Krieger and James Sumowski discuss developments in understanding and managing the cognitive deficits associated with MS.Medscape Neurology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery Commentary Source Type: news
Condition:   Multiple Sclerosis Intervention:   Other: Rehabilitative treatment protocol Sponsor:   University of Roma La Sapienza Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
To add more evidence to the controversial debate over stopping immunomodulatory therapy for multiple sclerosis after age 60, researchers focus on quality of life, walking performance, and relapse rates.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Conclusions Physiotherapy interventions can be a safe and beneficial option for spasticity in people with multiple sclerosis. No firm conclusion can be drawn on overall spasticity. Further researches in different spasticity aspects are needed.
Source: American Journal of Physical Medicine and Rehabilitation - Category: Rehabilitation Tags: Original Research Articles Source Type: research
More News: Brain | Health | Multiple Sclerosis | Neurology | Neurosurgery